2-Methoxy-cyclohexan-aldehyd | 62519-41-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methoxy-cyclohexan-aldehyd
• 英文别名: 2-Methoxycyclohexane-1-carbaldehyde
• CAS: 62519-41-9
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: IHSRLLUTDXQOGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation
  申请人：Sankyo Company Limited

  公开号：EP0542411A2

  公开（公告）日：1993-05-19

  Compounds of formula (I): in which: R¹ is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl, carboxy, alkoxycarbonyl, carbamoyl, cyano, nitro, alkanesulphonyl, haloalkanesulphonyl or sulphamoyl; R² is optionally substituted alkanoyl, optionally substituted alkenoyl, optionally substituted cycloalkylcarbonyl, substituted benzoyl, or 5,6-dihydro-1,4,2-dioxazin-3-yl; R³ is hydrogen, hydroxy, optionally substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy, cycloalkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aralkyloxycarbonylxy, phthalidyloxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or nitro; Y is -NH- or oxygen or sulphur; n is 1 to 5; and tautomers and salts of said compounds of formula (I), have the ability to inhibit blood platelet aggregation, and can thus be used for treatment and prophylaxis of thrombosis and embolisms.

  式(I)化合物： 其中R¹ 是氢、烷基、卤素、卤代烷基、羟基、烷氧基、卤代烷氧基、烷硫基、卤代烷硫基、氨基、烷酰基、卤代烷酰基、羧基、烷氧羰基、氨基甲酰基、氰基、硝基、烷磺酰基、卤代烷磺酰基或磺酰基；R² 是任选取代的烷酰基、任选取代的烯酰基、任选取代的环烷基羰基、取代的苯甲酰基或 5,6-二氢-1,4,2-二恶嗪-3-基；R³ 是氢、羟基、任选取代的烷氧基、烷氧基、烷甲氧基、烯甲氧基、环烷基羰基氧基、芳基羰基氧基、烷氧基羰基氧基、烷氧基羰基氧基、酞酰氧基、(5-甲基-2-氧代-1,3-二氧戊烯-4-基)甲氧基、(5-苯基-2-氧代-1,3-二氧戊烯-4-基)甲氧基、任选取代的氨基或硝基；Y 是-NH-或氧或硫；n 是 1 至 5；所述式（I）化合物的同系物和盐具有抑制血小板聚集的能力，因此可用于血栓和栓塞的治疗和预防。
• CYCLIC AMINO COMPOUNDS
  申请人：Sankyo Company Limited

  公开号：EP1063230A1

  公开（公告）日：2000-12-27

  Cyclic amino compounds represented by general formula (I) or pharmacologically acceptable salts thereof having an excellent antiplatelet aggregation effect; etc. and thus being useful as preventives or remedies for embolism, thrombosis or arterial sclerosis wherein R1 represents optionally substituted phenyl; R2 represents optionally substituted aliphatic acyl, optionally substituted benzoyl or alkoxycarbonyl; and R3 represents substituted and optionally ring-fused saturated cyclic amino.

  通式(I)代表的环状氨基化合物或其药理上可接受的盐，具有优异的抗血小板聚集作用等，因此可作为栓塞、血栓形成或动脉硬化的预防剂或治疗剂 其中R1代表任选取代的苯基；R2代表任选取代的脂肪族酰基、任选取代的苯甲酰基或烷氧基羰基；R3代表取代的和任选环融的饱和环状氨基。
• PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME
  申请人：Shiseido Company, Ltd.

  公开号：EP2255780A1

  公开（公告）日：2010-12-01

  The present invention provides a parakeratosis inhibitor, a pore-shrinking agent, and a rough skin inhibiting or ameliorating agent comprising, as an active ingredient, a compound that has excellent effects and high safety without safety problems such as sensory irritation, and provides an external composition for skin containing the same. The compound is selected from the glutamic acid derivatives represented by formula (1) or (2) and the salts thereof: wherein A represents a carbamoyl group, a benzyloxycarbonyl group, an alkyl group having 1 to 3 carbon atoms, an allyl group, or an amidino group; wherein Z represents an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, etc.; Y represents OH, an alkyloxy group having 1 to 3 carbon atoms, an allyloxy group, or NR3R4; R1 to R4 each independently represents H, an alkyl group having 1 to 3 carbon atoms, an allyl group, a cycloalkyl group having 3 to 7 carbon atoms, a cycloalkenyl group having 3 to 7 carbon atoms, a phenyl group, or a benzyl group, or R1 and R2, or R3 and R4, independently form a heterocycle.

  本发明提供了一种角化抑制剂、毛孔收缩剂和皮肤粗糙抑制或改善剂，其活性成分包括一种效果优异、安全性高且不存在感官刺激等安全问题的化合物，并提供了一种含有该化合物的皮肤外用组合物。该化合物选自式（1）或（2）代表的谷氨酸衍生物及其盐类： 其中 A 代表氨基甲酰基、苄氧羰基、具有 1 至 3 个碳原子的烷基、烯丙基或脒基； 其中 Z 代表具有 1 至 4 个碳原子的烷基、具有 2 至 4 个碳原子的烯基等。R1 至 R4 各自独立地代表 H、具有 1 至 3 个碳原子的烷基、烯丙基、具有 3 至 7 个碳原子的环烷基、具有 3 至 7 个碳原子的环烯基、苯基或苄基，或 R1 和 R2 或 R3 和 R4 独立地形成杂环。
• Treatment of laminitis with platelet aggregation inhibitors
  申请人：Dussler, Sabine

  公开号：EP2497475A1

  公开（公告）日：2012-09-12

  The present invention relates to the novel use of platelet aggregation inhibitors for the treatment and/or prevention of Laminitis in veterinary medicine. In particular the invention refers to the novel use of specific antiplatelet drugs for the treatment and/or prevention of Laminitis.

  本发明涉及在兽医学中使用血小板聚集抑制剂治疗和/或预防蹄叶炎的新方法。特别是，本发明涉及特定抗血小板药物在治疗和/或预防蹄叶炎方面的新用途。
• Tanning agents and preservatives
  申请人：Huffer Stephan

  公开号：US20060053564A1

  公开（公告）日：2006-03-16

  Aqueous formulations are prepared by a process wherein at least one cyclic compound of the formula I is heated in the presence of water and of an acidic catalyst and, during or after the heating, H—X—R 3 is at least partially separated off, where, in formula I, X is selected from oxygen, sulfur and N—R 6 , R 3 and R 6 are identical or different and are selected from C 1 -C 12 -alkyl, C 3 -C 12 -cycloalkyl, substituted or unsubstituted, C 7 -C 13 -aralkyl, C 6 -C 14 -aryl, substituted or unsubstituted, formyl, CO—C 1 -C 12 -alkyl, CO—C 3 -C 12 -cycloalkyl, substituted or unsubstituted, CO—C 7 -C 13 -aralkyl, CO—C 6 -C 14 -aryl, where, if X is N—R 6 , R 3 and R 6 may be linked to one another with formation of a ring; R 1 , R 2 and R 4 are identical or different and are selected from hydrogen, C 1 -C 12 -alkyl, C 3 -C 12 -cycloalkyl, substituted or unsubstituted, C 7 -C 13 -aralkyl, C 6 -C 14 -aryl, substituted or unsubstituted, it being possible in each case for two neighboring radicals to be linked to one another with formation of a ring; n is an integer from 1 to 4; R 5 are identical or different and are selected from hydrogen, C 1 -C 12 -alkyl, C 3 -C 12 -cycloalkyl, substituted or unsubstituted, C 7 -C 13 -aralkyl, C 6 -C 14 -aryl, substituted or unsubstituted, it being possible for R 5 to be linked to R 4 or in each case two neighboring radicals R 5 to be linked to one another with formation of a ring.

  水基制剂的制备方法是：将至少一种式 I 的环状化合物在水和酸性催化剂存在下加热，在加热过程中或加热后，H-X-R 在水和酸性催化剂存在下加热，在加热过程中或加热后，H-X-R 3 至少部分分离，其中，在式 I 中 X 选自氧、硫和 N-R 6 , R 3 和 R 6 相同或不同，且选自 C 1 -C 12 -烷基、C 3 -C 12 -取代或未取代的环烷基，C 7 -C 13 -芳烷基，C 6 -C 14 -芳基，取代或未取代，甲酰基，CO-C 1 -C 12 -烷基、CO-C 3 -C 12 取代或未取代的环烷基、CO-C 3 -C 12 7 -C 13 -芳烷基、CO-C 6 -C 14 -芳基，其中，如果 X 是 N-R 6 , R 3 和 R 6 可相互连接形成一个环； R 1 , R 2 和 R 4 相同或不同，且选自氢、C 1 -C 12 -烷基、C 3 -C 12 -取代或未取代的环烷基，C 7 -C 13 -芳烷基，C 6 -C 14 -芳基，取代或未取代，在每种情况下，两个相邻基都有可能相互连接形成环；n 是 1 到 4 的整数； R 5 相同或不同，选自氢、C 1 -C 12 -烷基、C 3 -C 12 -取代或未取代的环烷基，C 7 -C 13 -芳烷基，C 6 -C 14 -芳基，取代或未取代，R 5 与 R 4 或在每种情况下两个相邻的基 R 5 相连，形成一个环。